Combination of immune- and chemo-
therapy has become a new trend in
cancer treatment. Food and Drug Administration (FDA)-approved immune-modulatory agent,
thalidomide, can modulate the related
proteins of upstream signaling pathway of programmed cell death-
ligand 1 (PD-L1), including nuclear
transcription factor κB (NF-κB),
hypoxia inducible factor-1α (HIF-1α),
epidermal growth factor receptor (EGFR), and
signal transducer and activator of transcription 3 (STAT3), all acting as key antitumor target
proteins. In this work, we conjugated
thalidomide with oxidized
cisplatin to construct multi-functional Pt(IV)
prodrugs, named thaliplatins 4-6, to investigate the anti-
tumor effect of immuno- and chemo-
therapy. Among them, thaliplatin 6 exerted remarkable cytotoxicity against the tested
cancer cell lines, showing 15-26 and 9-20 times higher IC50 values than those of single
cisplatin or the combination of
cisplatin +
thalidomide, respectively. Moreover, thaliplatin 6 could rapidly accumulated into cells, markedly triggered DNA damage, and induced cell S phase arrest and apoptosis, as well as inhibited cell migration and invasion in
breast carcinoma cell line (MCF-7). Fluorescent confocal and western blotting experiments proved that 6 significantly regulated NF-κB, EGFR, HIF-1α and phosphor-
signal transducer and activator of transcription 3 (p-STAT3), and simultaneously inhibited PD-L1 expression to interrupt programmed cell death 1 (PD-1)/PD-L1 signaling pathway, suggesting a synergistic action of
cisplatin and
thalidomide. Most strikingly, in vivo tests indicated that 6 effectively decreased
tumor growth with no observable systemic toxicity, being superior to the anticancer efficacy of
cisplatin.